Journal: Oncology Letters

Article Title: Increased soluble E‑cadherin of spheroid formation supplemented with fetal bovine serum in colorectal cancer cells

doi: 10.3892/ol.2023.13793

Figure Lengend Snippet: Cell viability changes after spheroid formation of colorectal cancer cells in different environments. (A) The SNU-C5 and SNU-C5/5-FUR cells were mock-treated with DMSO or treated with indicated doses of 5-FU for 3 days. The extent of cell viability was determined by MTT assay. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01 and ***P<0.001 vs. DMSO; # P<0.05 and ## P<0.01 vs. sphere/GF. (B) The SNU-C5 and SNU-C5/5-FUR cells were mock-treated with DMSO or treated with indicated doses of 5-FU for indicated days. The extent of cell viability was determined by MTT assay using the aforementioned procedures. Data are presented as the mean ± SD (n=3). (C) Expression levels of cell cycle-related proteins in monolayer and spheroid formation cultures in SNU-C5 and SNU-C5/5-FUR cells were detected by immunoblotting. Immunoblotting analysis was performed for p21, β-catenin and GSK3β, while GAPDH was used for a loading control. Band density was analyzed by AzureSpot analysis software, and results are expressed as the mean ± SD (n=3). **P<0.01 and ***P<0.001 vs. monolayer; ## P<0.01 vs. sphere/FBS. 5-FU, 5-fluorouracil; FBS, fetal bovine serum; GF, growth factor.

Article Snippet: CREB (1:1,000; cat. no. CSB-PA005947HA01HU; Cusabio Technology, LLC), fibronectin (1:2,000; cat. no. CL54951AP; Cedarlane Laboratories), p21 (1:1,000; cat. no. 60214-1; Proteintech Group, Inc.) and p90RSK (Ab348; 1:1,000; cat. no. 79-554; Prosci, Inc.) were obtained from the corresponding listed company.

Techniques: MTT Assay, Expressing, Western Blot, Control, Software

Journal: Oncology Letters

Article Title: Increased soluble E‑cadherin of spheroid formation supplemented with fetal bovine serum in colorectal cancer cells

doi: 10.3892/ol.2023.13793

Figure Lengend Snippet: Densitometric results of western blotting on SNU-C5 and SNU-C5/5-FUR cells.

Article Snippet: CREB (1:1,000; cat. no. CSB-PA005947HA01HU; Cusabio Technology, LLC), fibronectin (1:2,000; cat. no. CL54951AP; Cedarlane Laboratories), p21 (1:1,000; cat. no. 60214-1; Proteintech Group, Inc.) and p90RSK (Ab348; 1:1,000; cat. no. 79-554; Prosci, Inc.) were obtained from the corresponding listed company.

Techniques: Western Blot, Marker

Journal: Scientific Reports

Article Title: Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood

doi: 10.1038/s41598-018-35470-9

Figure Lengend Snippet: Comparison of PIK3CA-H1047R mutant allele frequencies in patients CF22 and CF23 before and after whole genome rolling-circle amplification (WG-RCA) of venous and fingerstick cfDNA. Genomic DNA from cell line MDA-MB-453 is used as a positive control for the PIK3CA-H1047R mutation. No template control, patient C22 buffy gDNA, and patient CF23 cfDNA samples are used as negative controls for PIK3CA-H1047R. Mutant allele frequencies for patient CF22 are comparable among unamplified cfDNA, WG-RCA venous cfDNA and WG-RCA fingerstick cfDNA. No mutation is detected in patient CF23 samples either before or after WG-RCA.

Article Snippet: We sequenced patient CF4 cfDNA using the Ion AmpliSeq TM Comprehensive Cancer Panel and confirmed that WG-RCA of venous cfDNA improves gene coverage and decreases allelic imbalance relative to an MDA kit (REPLI-g Mini Kit, Qiagen) despite using an excess input of cfDNA (~35–40 ng) for whole genome amplification (Supplementary Fig. ).

Techniques: Mutagenesis, Amplification, Positive Control